by Maria Zannes | Sep 6, 2019 | Articles, News
AUGUST 29, 2019 As published in the San Antonio Business Journal By W. Scott Bailey – Senior Reporter, San Antonio Business Journal While there is acknowledgment that women have made progress in their climb to executive-level positions in San Antonio’s...
by Maria Zannes | Mar 6, 2019 | News
BioAffinity Technologies is proud to be named a finalist in the Lyfebulb Helsinn 2019 Innovation Summit in Oncology. Lyfebulb-Helsinn Innovation Summit March 18 and 19, 2019 Monaco, Principality of Monaco Ten finalists will compete at the second annual...
by Maria Zannes | Oct 12, 2018 | News
OCTOBER 10, 2018 As published in Genome Web’s 360Dx NEW YORK, NY – BioAffinity Technologies today said that it has inked a licensing agreement with Precision Pathology Services for the continued development and commercial sale of its CyPath Lung assay as a...
by Maria Zannes | Oct 12, 2018 | News
OCTOBER 10, 2018 As published in the San Antonio Business Journal By W. Scott Bailey – Senior Reporter, San Antonio Business Journal BioAffinity Technologies, a San Antonio-based biotech, has struck a deal with another local company, Precision Pathology Services, to...
by Maria Zannes | Jul 24, 2018 | News
JULY 20, 2018 As published in GenomeWeb’s 360Dx By Leo O’Connor NEW YORK – BioAffinity Technologies has begun clinical validation of a test for the early detection of lung cancer that uses flow cytometry and detects porphyrin molecules in sputum samples. The San...
by Maria Zannes | Jul 24, 2018 | News
JULY 19, 2018 As published in the San Antonio Business Journal By W. Scott Bailey Roughly four years after its San Antonio launch, cancer diagnostics company bioAffinity Technologies is only months away from taking its initial product — CyPath Lung — to market. The...
